# A Clinical Trial Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1019-1 and BR1019-2 in Healthy Adult Subjects

> **NCT05875259** · PHASE1 · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 36 (actual)

## Conditions studied

- Hypertension
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** BR1019-1
- **DRUG:** BR1019-2
- **DRUG:** BR1019-1 + BR1019-2

## Key facts

- **NCT ID:** NCT05875259
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-13
- **Primary completion:** 2023-06-29
- **Final completion:** 2023-06-29
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05875259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05875259, "A Clinical Trial Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1019-1 and BR1019-2 in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05875259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*